Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Ascendis Pharma A/S ADR’s stock clocked out at $201.16, up 2.63% from its previous closing price of $196.01. In other words, the price has increased by $2.63 from its previous closing price. On the day, 0.52 million shares were traded. ASND stock price reached its highest trading level at $203.0 during the session, while it also had its lowest trading level at $195.0.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Raymond James on October 17, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $271.
Morgan Stanley Upgraded its Equal-Weight to Overweight on May 05, 2025, while the target price for the stock was maintained at $250.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 09 ’25 when JENSEN FLEMMING STEEN bought 5,000 shares for $203.70 per share.
JENSEN MICHAEL WOLFF bought 5,000 shares of ASND for $965,000 on Aug 29 ’25. On Aug 27 ’25, another insider, PEDERSEN ANNI LOTTE KIRSTINE S, who serves as the Officer of the company, bought 3,036 shares for $193.94 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ASND now has a Market Capitalization of 12181125120 and an Enterprise Value of 12457086976. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.79. Its current Enterprise Value per Revenue stands at 25.384 whereas that against EBITDA is -50.109.
Stock Price History:
The Beta on a monthly basis for ASND is 0.45, which has changed by 0.5552646 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, ASND has reached a high of $216.45, while it has fallen to a 52-week low of $118.03. The 50-Day Moving Average of the stock is -0.29%, while the 200-Day Moving Average is calculated to be 16.19%.
Shares Statistics:
It appears that ASND traded 424.67K shares on average per day over the past three months and 347900 shares per day over the past ten days. A total of 60.55M shares are outstanding, with a floating share count of 60.13M. Insiders hold about 0.70% of the company’s shares, while institutions hold 105.36% stake in the company. Shares short for ASND as of 1761868800 were 3549505 with a Short Ratio of 8.06, compared to 1759190400 on 2562570. Therefore, it implies a Short% of Shares Outstanding of 3549505 and a Short% of Float of 7.049999999999999.
Earnings Estimates
Ascendis Pharma A/S ADR (ASND) is presently subject to a detailed evaluation by 11.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.1, with high estimates of $0.88 and low estimates of -$1.17.
Analysts are recommending an EPS of between -$1.19 and -$3.87 for the fiscal current year, implying an average EPS of -$2.21. EPS for the following year is $3.35, with 13.0 analysts recommending between $7.46 and -$0.55.
Revenue Estimates
In. The current quarter, 11 analysts expect revenue to total $210.87M. It ranges from a high estimate of $233M to a low estimate of $196.31M. As of. The current estimate, Ascendis Pharma A/S ADR’s year-ago sales were $57.83MFor the next quarter, 11 analysts are estimating revenue of $263.54M. There is a high estimate of $294M for the next quarter, whereas the lowest estimate is $224.37M.
A total of 13 analysts have provided revenue estimates for ASND’s current fiscal year. The highest revenue estimate was $777M, while the lowest revenue estimate was $679.68M, resulting in an average revenue estimate of $734.32M. In the same quarter a year ago, actual revenue was $363.64MBased on 13 analysts’ estimates, the company’s revenue will be $1.33B in the next fiscal year. The high estimate is $1.6B and the low estimate is $1.06B.
